Posted by Michael Wonder on 01 Sep 2020
Health Canada authorises Enspryng for Canadians living with neuromyelitis optica spectrum disorder
31 August 2020 - Roche Canada announced today that Health Canada has granted market authorisation for Enspryng (satralizumab) as monotherapy or in combination with immunosuppressive therapy for the treatment of neuromyelitis optica spectrum disorder in adult and adolescent patients who are anti-aquaporin 4 seropositive.
Canada is the first country to receive health authority approval for Enspryng, offering a new treatment option for people living with neuromyelitis optica spectrum disorder.
The Health Canada market authorisation of Enspryng was based on data from two phase 3 randomised, multi-centre, double-blind, placebo-controlled clinical trials, SAkuraSky and SAkuraStar.
